文献速递前列腺癌

BRCAness与前列腺癌:诊断和治疗考量

BRCAness and prostate cancer: diagnostic and therapeutic considerations.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-08-21

本综述围绕DNA修复突变与前列腺癌的关系,梳理了转移性前列腺癌中DNA修复突变的检测方法(包括胚系测序、体细胞测序、游离DNA检测和循环肿瘤细胞检测)及临床病程与治疗策略。结论认为,对转移性前列腺癌患者获取胚系和体细胞肿瘤基因组测序是合理的,有助于指导PARP抑制剂或卡铂等治疗决策;未来游离DNA测序可能帮助阐明PARP抑制剂耐药机制(包括回复突变)。

要点

  • 转移性前列腺癌患者可考虑胚系和体细胞肿瘤基因组测序以指导治疗。
  • DNA修复突变可通过胚系、体细胞、游离DNA和循环肿瘤细胞等多种方法检测。
  • 未来游离DNA测序可能帮助阐明PARP抑制剂耐药机制如回复突变。

核心结论

  • 对转移性前列腺癌患者获取胚系遗传测序和体细胞肿瘤基因组测序是合理的,可帮助指导未来可能包括PARP抑制剂或卡铂的治疗决策。
  • 未来对PARP抑制剂进展的转移性去势抵抗性前列腺癌患者,游离DNA测序可能帮助阐明耐药机制,包括回复突变。

研究设计与样本

  • 本综述概述了与转移性前列腺癌DNA修复突变患病率和检测相关的正在进行的研究和近期发表文献。

主要发现

  • 综述讨论了通过多种诊断方法检测DNA修复突变,包括胚系测序、体细胞测序、游离DNA检测和循环肿瘤细胞检测。
  • 综述探讨了携带DNA修复基因突变的前列腺癌患者的临床病程及该人群的治疗策略。

临床怎么用

  • 对转移性前列腺癌患者,可获取胚系遗传测序和体细胞肿瘤基因组测序以辅助治疗决策。
  • 治疗决策未来可能包括PARP抑制剂或卡铂。
  • 对PARP抑制剂进展的转移性去势抵抗性前列腺癌患者,可考虑游离DNA测序以探索耐药机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent advances in genetic sequencing and recent studies focusing on the broader use of Poly ADP Ribose polymerase (PARP) inhibitors have led to an upsurge of interest in DNA repair mutations as they relate to prostate cancer. METHODS: This review outlines ongoing studies and recent publications as they relate to the prevalence and detection of DNA repair mutations in metastatic prostate cancer. The detection of these mutations through multiple diagnostic approaches is discussed, including germline sequencing, somatic sequencing, cell-free DNA assays, and circulating tumor cell assays. The clinical course of patients with prostate cancer and DNA repair gene mutations is explored in addition to therapeutic strategies for this population. CONCLUSIONS: In men with metastatic prostate cancer, it is reasonable to obtain germline genetic sequencing as well as somatic tumor genomic sequencing to help guide further treatment decisions that may include PARP inhibitors or carboplatin in the future. In the future, in men with metastatic castrate resistant prostate cancer with progression on PARP inhibitors, cell-free DNA sequencing may help elucidate mechanisms of resistance, which include reversion mutations.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Dhawan M, Ryan CJ. BRCAness and prostate cancer: diagnostic and therapeutic considerations. Prostate Cancer Prostatic Dis. 2018. PMID: 30131605. doi:10.1038/s41391-018-0069-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。